Renal Safety of Tenofovir in Lesotho
Author Information
Author(s): Bygrave Helen, Kranzer Katharina, Hilderbrand Katherine, Jouquet Guillaume, Goemaere Eric, Vlahakis Nathalie, Triviño Laura, Makakole Lipontso, Ford Nathan
Primary Institution: Médecins Sans Frontières, Morija, Lesotho
Hypothesis
What is the prevalence of abnormal renal function at baseline and the factors associated with it in a community cohort in Lesotho?
Conclusion
In this setting, TDF-associated renal toxicity is rare and mainly transient.
Supporting Evidence
- Among 933 adults, 176 (18.9%) had a baseline creatinine clearance <50 ml/min.
- Renal function improved during follow-up with a median change in creatinine clearance of +5 ml/min at 6 months.
- Only one case of severe renal impairment was reported among those who initiated TDF.
Takeaway
This study looked at how safe a medicine called Tenofovir is for the kidneys in people in Lesotho. It found that most people didn't have serious kidney problems from it.
Methodology
The study analyzed changes in creatinine clearance from baseline for patients initiated on TDF at 6 and 12 months and developed screening algorithms using risk factors determined by multivariate analysis.
Potential Biases
The use of operational data may introduce bias due to missing data and limited covariates for analysis.
Limitations
The study was limited by the lack of consensus on the formula to calculate creatinine clearance and missing data.
Participant Demographics
The median age was 40.6 years, with 62.5% being women.
Statistical Information
P-Value
0.0002
Confidence Interval
95% CI 5.44–23.98
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website